by admin | 11 February 2022 | News
Presentation at Bio CEO & Investor Conference by admin | 10 February 2022 | News
February 10, 2022, New York, NY – Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announced today that Dr Kunwar Shailubhai, Chief Executive Officer... by admin | 4 February 2022 | News
– Tiziana is Developing the First Oral Form of Foralumab in a Convenient Capsule to be Evaluated in Phase 1b Clinical Study New York, February 4, 2022 – Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling... by admin | 26 January 2022 | News
NEW YORK – 26 January 2022 – Tiziana Life Sciences Ltd (NASDAQ: TLSA) (“Tiziana” or the “Company”), a clinical-stage biopharmaceutical company developing breakthrough therapies for KRAS+ Non-Small Cell Lung Cancer (NSCLC) and transformational... by admin | 24 January 2022 | News
NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that its Board of Directors has today authorized the Company’s management to implement a stock repurchase program for up to $5 million of the Company’s common shares... by admin | 13 January 2022 | News
New York, January 13, 2022 – Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that Dr. Thomas Adams passed away on January 9, 2022. He served as a... by admin | 10 January 2022 | News
– Clinical data from the first patient, after completing 3 out of 6 months, suggest that the treatment was well tolerated with a favorable clinical response – FDA allows for continued enrollment under the Individual Patient Expanded Access Program New... by admin | 6 January 2022 | News
NEW YORK, January 6, 2022 – Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that senior management will present at the Biotech Showcase Conference... by admin | 23 December 2021 | News
London, 23 December 2021 – Tiziana Life Sciences(Nasdaq: TLSA) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases has added some additional information on its website for shareholders regarding the... by admin | 21 October 2021 | News
London/New York, 21 October 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Old Tiziana”) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announced on 20 August 2021 that it... by admin | 20 October 2021 | News
London/New York, 20 October 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Old Tiziana”) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announced on 20 August 2021 that it... by admin | 20 October 2021 | News
London, New York, 20 October 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today... by admin | 19 October 2021 | News
London/New York, 19 October 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Old Tiziana”) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announced on 20 August 2021 that it... by admin | 6 October 2021 | News
London, New York, 6 October 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today... by admin | 5 October 2021 | News
London, New York, 5 October 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today... by admin | 4 October 2021 | News
London, New York, 4 October 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today... by admin | 28 September 2021 | News
London, New York, 28 September 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today... by admin | 27 September 2021 | News
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT CONTAINS INSIDE... by admin | 24 September 2021 | News
London, 24 September 2021 – Tiziana Life Sciences plc (“Tiziana”, LSE: TILS, NASDAQ: TLSA), a biotechnology company a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces its interim results for... by admin | 7 September 2021 | News
London/New York, 7 September 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Old Tiziana”) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announces that with immediate... by admin | 7 September 2021 | News
NEW YORK and LONDON, September 7, 2021 — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, will host... by admin | 3 September 2021 | News
London/New York, 3 September 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Old Tiziana”) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announced on 20 August 2021 that... by admin | 2 September 2021 | News
Precision Gains Access to Tiziana’s Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio Durham, N.C., New York, N.Y. and London, September 2, 2021 – Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage... by admin | 20 August 2021 | News
London/New York, August 20, 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Old Tiziana”) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces that it has...